A

Allogene Therapeutics

D
ALLO
USD
0.205
(6.8447%)
Market Closed
121,037.00
Volume
-1.37
EPS
-
Div Yield
-2.012579
P/E
669,156,851.20
Market Cap
Today
-0.4666%
1 Week
25.245%
1 Month
24.031%
6 Months
9.777%
12 Months
-2.290%
Year To Date
0.000%
All Time
0%

Title:
Allogene Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research anddevelopment efforts.
Do you need help or have a question?